Brightstar Capital Partners in its acquisition of Analyte Health, a provider of digital health services
Waters Corporation (NYSE: WAT) in its pending $39 billion Reverse Morris Trust combination with Becton, Dickinson and Company’s (NYSE: BDX) Biosciences & Diagnostics Solutions business to create a life sciences and diagnostics leader
BayPine in its acquisition of CenExel Clinical Research, a provider of a clinical trial site network
Bain Capital-backed QuVa Pharma in its acquisition of LogicStream
Owens & Minor in its proposed $1.4 billion acquisition of Rotech Healthcare Holdings
Waud Capital Partners in its acquisition of Mopec, a provider of anatomic and forensic pathology equipment, technology, consumable products and services, from Blackford Capital
VSP Vision in its acquisition of Eyemart Express from FFL Partners and Leonard Green & Partners
Leerink Partners, Morgan Stanley, Cantor Fitzgerald and Oppenheimer & Co. as placement agents in connection with the $260 million PIPE financing commitment for Helix Acquisition Corp. II (NASDAQ: HLXB), a SPAC sponsored by affiliates of Cormorant Asset Management, to combine with BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company advancing novel small-molecule therapeutics, which was initially formed as a subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO)